The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials

Purpose: Several meta-analyses reported berberine (BBR) supplementation improves glycemic parameters and inflammatory marker, but findings remain inconsistent. Therefore, this study was conducted. Methods: We systematically searched PubMed, Embase, Web of Science, Scopus, and Google Scholar to identify the relevant meta-analyses up to April 2023. Findings: BBR supplementation was effective in reducing fasting blood glucose (FBG) (ESWMD: - 0.77; 95% CI: - 0.90 to - 0.63, and ESSMD: - 0.65; 95% CI: - 0.83 to - 0.47), hemoglobin A1C (HbA1C) (ESWMD: - 0.57; 95% CI: - 0.68 to - 0.46), homeostasis model assessment for insulin resistance (HOMA-IR) (ESWMD: - 1.04; 95% CI: - 1.66 to - 0.42, and ESSMD: - 0.71; 95% CI: - 0.97 to - 0.46), insulin (ESWMD: - 1.00; 95% CI: - 1.70 to - 0.30, and ESSMD: - 0.63; 95% CI: - 0.94 to - 0.32), interleukin (IL) -6 (ESSMD: - 1.23; 95% CI: - 1.61 to - 0.85), tumor necrosis factor- a (TNF- a) (ESSMD: - 1.04; 95% CI: - 1.28 to - 0.79), and C-reactive protein (CRP) (ESWMD: - 0.62; 95% CI: - 0.74 to - 0.50, and ESSMD: - 1.70; 95% CI: - 2.21 to - 1.19). Implications: The finding of our umbrella showed that the supplementation of BBR could be effective in improving glycemic parameters and inflammatory marker in adults.